Ocular Therapeutix™ Executive Chairman Pravin U. Dugel, MD Becomes President and CEO Antony Mattessich is Stepping Down as President and CEO
April 15, 2024 07:00 ET
|
Ocular Therapeutix, Inc.
BEDFORD, Mass., April 15, 2024 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ:OCUL) (“Ocular”), a biopharmaceutical company committed to enhancing people’s vision and quality of life through...
Ocular Therapeutix Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) to Senior Vice President of Global Head of Biometrics
April 09, 2024 07:30 ET
|
Ocular Therapeutix, Inc.
BEDFORD, Mass., April 09, 2024 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ:OCUL) (“Ocular”), a biopharmaceutical company committed to enhancing people’s vision and quality of life through...
Ocular Therapeutix™ Announces Positive Phase 2 PAXTRAVA™ Glaucoma Data at the American Society of Cataract and Refractive Surgery 2024 Annual Meeting
April 06, 2024 10:00 ET
|
Ocular Therapeutix, Inc.
Phase 2 data highlight consistent and sustained reductions in Intraocular Pressure (IOP), statistically significant (p<0.0001) through six months, with clinically meaningful reductions of 24-30%...
Ocular Therapeutix™ To Present Data at the 2024 ASCRS Annual Meeting (American Society of Cataract and Refractive Surgery)
March 26, 2024 07:30 ET
|
Ocular Therapeutix, Inc.
BEDFORD, Mass., March 26, 2024 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ:OCUL, “Ocular”, the “Company”), a biopharmaceutical company committed to enhancing people’s vision and quality of...
Ocular Therapeutix™ Reports Fourth Quarter and Full Year 2023 Results
March 11, 2024 16:05 ET
|
Ocular Therapeutix, Inc.
Leadership Appointments Move Ocular Towards Being a Leader in Retinal Care Screening Underway in AXPAXLI™ Phase 3 SOL-1 Trial for Wet AMD Topline Clinical Data for AXPAXLI in Diabetic Retinopathy...
Ocular Therapeutix™ to Release Fourth Quarter and Full Year 2023 Results on March 11, 2024
March 05, 2024 07:30 ET
|
Ocular Therapeutix, Inc.
BEDFORD, Mass., March 05, 2024 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ:OCUL, the “Company”), a biopharmaceutical company committed to enhancing people’s vision and quality of life...
Ocular Therapeutix Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) to Newly Appointed Executive Chairman and Chief Strategy Officer
February 22, 2024 07:32 ET
|
Ocular Therapeutix, Inc.
BEDFORD, Mass., Feb. 22, 2024 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ:OCUL) (“Ocular”), a biopharmaceutical company committed to enhancing people’s vision and quality of life through...
Ocular Therapeutix, Inc. Announces $325.0 Million Private Placement
February 22, 2024 07:31 ET
|
Ocular Therapeutix, Inc.
BEDFORD, Mass., Feb. 22, 2024 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (Nasdaq:OCUL) (the “Company”), a biopharmaceutical company committed to enhancing people’s vision and quality of life...
Ocular Therapeutix™ Announces Board of Directors and Leadership Updates
February 22, 2024 07:30 ET
|
Ocular Therapeutix, Inc.
Industry Leader and Retina Expert, Pravin U. Dugel, MD, Becomes Executive Chair Jeffrey S. Heier, MD to become Chief Scientific Officer, Peter K. Kaiser, MD to be Medical Director, and Sanjay...
Ocular Therapeutix™ Appoints Steve Meyers to Chief Commercial Officer
February 15, 2024 08:00 ET
|
Ocular Therapeutix, Inc.
BEDFORD, Mass., Feb. 15, 2024 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ:OCUL), a biopharmaceutical company focused on the formulation, development, and commercialization of innovative...